IFAH-Europe welcomes Parliament's firm steps in the right direction for animal health

Written by IFAH-Europe on 11 March 2016 in Press Release
Press Release

Brussels, 10 March 2016 – Coming just days after the adoption of the new framework legislation on transmissible animal diseases, IFAH-Europe welcomes the strong signals sent today by the European Parliament to ensure the availability of a varied arsenal of veterinary medicines for the prevention and treatment of animal disease.

Brussels, 10 March 2016 – Coming just days after the adoption of the new framework legislation on transmissible animal diseases, IFAH-Europe welcomes the strong signals sent today by the European Parliament to ensure the availability of a varied arsenal of veterinary medicines for the prevention and treatment of animal disease.

We are particularly encouraged by the Parliament’s efforts to stimulate improvements of existing medicines which can lead to enhanced treatments in terms of reduction of dosage, improved potency, as well as increasing ease of use for the animal owner. By putting in place more efficient procedures to authorise medicines in exceptional situations, this paves the way for greater preparedness in the case of disease outbreaks. Also, encouraging investment in innovation means that new medicines may be developed to fill the gaps in treatment options for animals that at present don’t exist.

The European animal health industry fully supports not only the banning of unjustified routine preventive treatment with antibiotics but also the restricted and controlled approach to online sales of antibiotics. As a sector we are strongly committed to promoting the responsible use of all medicines in veterinary care.

Commenting after the vote IFAH-Europe’s Secretary General Roxane Feller said, “Europe has one of the world’s most stringent regulatory systems for controlling medicines, with an unusually high administrative burden associated with the licensing of veterinary medicines (double that of human medicines). This opportunity to revise the rules governing our products only comes up every 10-15 years. Subsequently, we very much appreciate the steps taken so far and hope to see the institutions further build on this base to boost innovation in animal health and increase the availability of prevention and treatment options for all of Europe’s animals, veterinarians, farmers and pet owners alike.”

The Parliament will now start talks with the Council of the EU and we look forward to the outcome of the negotiations.

 

NOTES TO EDITORS:
•    Read IFAH-Europe’s position on the veterinary medicines and the medicated feed proposals.

 

 

About the author

IFAH-Europe is the representative body of manufacturers of veterinary medicines, vaccines and other animal health products in Europe. It represents originators and generics alike, as well as large, medium-sized and small companies. IFAH-Europe promotes a single market in veterinary medicines across the EU ensuring the availability of medicines to protect the health and welfare of all animals. Follow IFAH-Europe on @IFAHEurope - Like us on Facebook: www.facebook.com/WeCare.petsEurope

For further information, please contact
Kim Hardie - Communications Director
Tel: +32 2 543 75 75
E-mail: k.hardie@ifahsec.org

 

Share this page

Tags

Categories

Partner content

This content is published by the Parliament Magazine on behalf of our partners.

Related Partner Content

PM+: GMO authorisation needs legal certainty
26 October 2015

Ahead of the European Parliament’s vote on the use of GMOs, Nathalie Moll calls for a shift to a more coherent and science-based approach to EU policymaking.

GMOs: Time to stand up for EU law and innovation
2 June 2016

MEPs have the chance to support innovation and evidence-based authorisation procedures when they meet next week in Strasbourg, says Pedro Narro Sanchez.